Prognostic Test for Cervical Cancer

**OCR Number:** OCR 4987

**Description:**

- Human papillomavirus (HPV) infection is the cause of cervical cancer.
- HPV DNA testing is a $1 billion market worldwide.
- Researchers at Yale have identified a specific HPV DNA methylation signature in cervical cells that may have prognostic value for cervical cancer.
- The DNA methylation test described here has the potential to accurately identify HPV DNA-positive women at minimal risk of developing cervical cancer.
- This test may be able to distinguish patients at minimal versus high-risk of progressing to cancer.

Examination of the HPV16 DNA methylation signature in HPV16-positive cervical samples showed that the level of methylation increased progressively and dramatically with the pathologic severity of the lesions.

**Published/Issued Patents:** [U.S. Pub. App. No. 20130137086](https://patents.google.com/patent/US20130137086A1)

**Publications:**

**Licensing Contact:** John Puziss
john.puziss@yale.edu